Physician profile
Daniel Aires
NPI 1467555359
$82,843.89
in general payments reported to CMS, 2019-2025
32 companies · $21K in 2025
The $21K reported for 2025 was more than what 94% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17K · 2020: $171 · 2022: $250 · 2023: $13K · 2024: $31K · 2025: $21K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $58K · Travel and Lodging: $4,146 · Food and Beverage: $3,012.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $58,065.00 |
| Travel and Lodging | $4,146.32 |
| Food and Beverage | $3,012.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $43,267.66 | 2023-2024 | Uvadex |
| Therakos LLC | $20,045.20 | 2025 | Uvadex, Cellex |
| Mallinckrodt Enterprises LLC | $16,344.16 | 2019 | |
| Abbvie INC. | $717.12 | 2019-2025 | |
| Pfizer INC. | $348.63 | 2019-2025 | |
| Genzyme Corporation | $323.45 | 2022-2025 | |
| Lilly USA, LLC | $273.29 | 2019-2025 | Taltz, Ebglyss |
| Ucb, INC. | $198.20 | 2024-2025 | Bimzelx |
| Novartis Pharmaceuticals Corporation | $180.71 | 2023-2025 | |
| Leo Pharma INC. | $176.07 | 2019-2025 | Adbry |
| Regeneron Healthcare Solutions, INC. | $145.39 | 2023-2025 | Dupixent |
| Incyte Corporation | $91.14 | 2024-2025 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $90.36 | 2023-2025 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $82.27 | 2019-2024 | |
| Amgen INC. | $71.71 | 2023-2025 | Otezla, Otezla |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $60.61 | 2019-2020 | |
| Organon LLC | $49.28 | 2025 | Vtama |
| Biofrontera INC. | $49.23 | 2024 | Ameluz, Xepi, Bf-Rhodoled |
| Helsinn Therapeutics (U.S.), INC. | $44.50 | 2019 | |
| Dermira, INC. | $34.37 | 2019 | |
| Botanix Sb INC | $31.83 | 2025 | Sofdra |
| Krystal Biotech INC | $27.57 | 2024 | Vyjuvek |
| Dermavant Sciences, INC. | $25.66 | 2024 | Vtama |
| Genentech USA, INC. | $25.48 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $22.25 | 2019 | |
| Cipher Pharmaceuticals US LLC | $22.17 | 2025 | Spinosad, Natroba |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.93 | 2025 | Jardiance |
| Almirall LLC | $19.90 | 2024 | Klisyri |
| Merck Sharp & Dohme LLC | $15.31 | 2020 | |
| Mayne Pharma Commercial LLC | $14.09 | 2019 | |
| Galderma Laboratories, L.P. | $13.61 | 2019 | |
| Celgene Corporation | $11.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Aires listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.